Indian drugmaker Biocon will introduce its insulin product Insugen in Germany through a marketing partnership, the company reported. Details of the agreement were not disclosed. This will be the third region outside of India where Insugen will be marketed; it is also available in parts of the Middle East and Africa.
"Germany is considered as one among the company's key markets in Europe apart from United Kingdom, Scandinavia and Eastern Europe," said Nehal Vora, head of the European markets department at Biocon. "We will continue to capitalize on the emerging opportunities here."
Insugen is generation recombinant, human bio-insulin. Biocon has already marketed several active pharmaceutical ingredients in Germany, such as statins, anti-diabetics and immunosuppressants.